Form 4: Rocket Pharmaceuticals Officer Sells Shares

Mark Andrew White, a General Manager at Rocket Pharmaceuticals, sold 12,532 shares of common stock on April 8, 2024, at a price of $24.638 per share.

Summary

• On April 8, 2024, Mark Andrew White, a General Manager at Rocket Pharmaceuticals, sold 12,532 shares of the company's common stock.
• The sale price was $24.638 per share.
• Following the transaction, White directly owns 75,226 shares of Rocket Pharmaceuticals.
• The holdings include Restricted Stock Units (RSUs) that convert to common stock on a one-for-one basis.
• RSUs vest one-third (1/3) upon the first anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over the following two years.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of an insider transaction. The sale itself doesn't necessarily indicate a positive or negative outlook.

Industry Context

This is a routine disclosure of an insider transaction. It's common for company executives to periodically sell shares for personal financial management.

Stakeholder Impact

• The sale of shares by an officer could be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the transaction.

Key Dates